Summary

Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Marshall Stoller (ucsf)
Headshot of Marshall Stoller
Marshall Stoller

Description

Summary

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.

Official Title

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria

Keywords

Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3), Primary Hyperoxaluria, PH1, PH2, RNAi, GalNAc, LDHA, LDH, siRNA, PH3, Primary hyperoxaluria type 1, Primary hyperoxaluria type 2, Inborn Genetic Diseases, nedosiran, DCR-PHXC, Open Label

Eligibility

You can join if…

•Participant successfully completed a Dicerna Pharmaceuticals, Inc. study of DCR PHXC.

OR Participant is the sibling of a participant who successfully completed a Dicerna Pharmaceuticals, Inc. study of DCR PHXC. Siblings must be younger than 18 years of age and must have genetically confirmed PH.

  • For participants rolling over from a multidose study of DCR-PHXC, enrollment should occur within a window of 25 to 75 days from the last dose of study intervention.
  • Estimated GFR at screening ≥ 30 mL/min normalized to 1.73 m2 body surface area (BSA), calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula in participants aged ≥ 18 years, or the multivariate equation by Schwartz in participants aged 12 months to 17 years. In Japan, the cystatin C-based Uemura formula will be used for participants aged 12 months to <2 years, the creatinine-based Uemura formula by will be used for participants aged 2 to 17 years, and the equation by Matsuo will be used in participants aged ≥ 18 years.

You CAN'T join if...

  • Renal or hepatic transplantation (prior or planned within the study period)
  • Plasma oxalate > 30 µmol/L
  • Currently on dialysis
  • Documented evidence of clinical manifestations of systemic oxalosis

Locations

  • Clinical Research Site
    San Francisco California 94143 United States
  • Clinical Trial Site
    Rochester Minnesota 55905 United States

Lead Scientist at University of California Health

  • Marshall Stoller (ucsf)
    My clinical and research efforts continue to be centered around the treatment and understanding the pathogenesis of urinary stone disease. I have recently identified zinc as a critical factor in the early mineralization process.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
ID
NCT04042402
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 75 study participants
Last Updated